IVF

SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice relates to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "10-K"), and its Quarterly Report on Form

8-K - INVO Fertility, Inc. (0001417926) (Filer)

10-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) Revenue was $6,841,250, an increase of 5% compared to $6,532,000.Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431.Revenue from all clinics was $8,021,929, including both consolidated and equity method clinics, an increase of 4% compared to $7,731,177.Net loss

NT 10-Q - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that on April 23, 2026, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Se

SCHEDULE 13G - INVO Fertility, Inc. (0001417926) (Subject)

NT 10-K - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. ("INVO") (NASDAQ:IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-5 reverse split of its issued and outstanding and of its authorized common stock effective as of 12:01 a.m. Eastern Time on March 27, 2026. Commencing with the opening of trading on The Nasdaq Capital Market on March 27, 2026, the Company's common stock will trade on a post-split basis under the same trading symbol, "IVF". As a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F880. As a result of the reverse stock split, every 5 shares of issued and out

SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced the adoption of time-lapse incubation technology at its Wisconsin clinic. This integration reflects INVO's commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to investing in laboratory excellence and clinical quality across its growing network of clinics. "INVO Fertility is proud to introduce this te

MIDDLETON, Wis. and SARASOTA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO Fertility" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that its Wisconsin Fertility Institute (WFI) clinic has joined the Progyny network. Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI's participation in the Progyny network significantly expands the clinic's acce

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest. The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025. Founded more than a decade ago, Family Beginnings has built a strong reputation for delivering compreh

424B3 - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040. INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilizatio

EFFECT - INVO Fertility, Inc. (0001417926) (Filer)

S-8 - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (NASDAQ:IVF) ("INVO" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today issued a shareholder letter from its Chief Executive Officer, Steve Shum, outlining the Company's strengthened fundamental position and its strategic outlook for continued growth. In the letter, management highlights meaningful progress across operations, acquisitions, and capital structure, positioning INVO Fertility for growth through both organic initiatives and strategic clinic acquisitions. Dear Fellow Shareholders, As

S-1 - INVO Fertility, Inc. (0001417926) (Filer)

8-K - INVO Fertility, Inc. (0001417926) (Filer)

SARASOTA, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility Inc. ("INVO" or the "Company") (NASDAQ:IVF), a healthcare company focused on the fertility market, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on December 3, 2025 (the "December 2025 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to a reduced exercise price of the outstanding December 2025 Warrants to an amended exercise price of $1.59, and to exercise the outstanding December 2025 Warrants to purchase an aggregate of 4,733,728 shares of the Company's common s

8-K - INVO Fertility, Inc. (0001417926) (Filer)